Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study-Reference-Cited by-同舟云学术

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

Published:2018-10 Issue:10 Volume:3 Page:671-680
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Feagan Brian G,Panés Julián,Ferrante Marc,Kaser Arthur,D'Haens Geert R,Sandborn William J,Louis Edouard,Neurath Markus F,Franchimont Denis,Dewit Olivier,Seidler Ursula,Kim Kyung-Jo,Selinger Christian,Padula Steven J,Herichova Ivona,Robinson Anne M,Wallace Kori,Zhao Jun,Minocha Mukul,Othman Ahmed A,Soaita Adina,Visvanathan Sudha,Hall David B,Böcher Wulf O

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference26 articles.

1. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: diagnosis and medical management;Gomollon;J Crohns Colitis,2017

2. Crohn's disease;Baumgart;Lancet,2012

3. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease;Terdiman;Gastroenterology,2013

4. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials;Peyrin-Biroulet;Clin Gastroenterol Hepatol,2008

5. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys;Gordon;Eur J Gastroenterol Hepatol,2015

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-interleukins;The Korean Journal of Gastroenterology;2024-08-25

2. Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?;Gut;2024-07-17

3. Biologics in Focus: A Comprehensive Review of Current Biological and Small Molecules Therapies for Crohn’s Disease in the United Arab Emirates (UAE);Gastrointestinal Disorders;2024-07-07

4. Single-Cell Transcriptomic and Targeted Genomic Profiling Adjusted for Inflammation and Therapy Bias Reveal CRTAM and PLCB1 as Novel Hub Genes for Anti-Tumor Necrosis Factor Alpha Therapy Response in Crohn’s Disease;Pharmaceutics;2024-06-19

5. Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease;Immunotherapy;2024-04-17